Entera Bio (NASDAQ:ENTX) Stock Jumps 6.9% – Should You Buy?

Posted by George Bondi on Sep 30th, 2026

Entera Bio Ltd. (NASDAQ:ENTX – Get Free Report)’s stock price shot up 6.9% during trading on Wednesday. The stock traded as high as $2.86 and last traded at $2.8750. 397,909 shares traded hands during mid-day trading, a decline of 61% from the average session volume of 1,022,903 shares. The stock had previously closed at $2.69.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on ENTX. HC Wainwright reiterated a “buy” rating on shares of Entera Bio in a research report on Wednesday, June 24th. Guggenheim assumed coverage on Entera Bio in a research note on Thursday, September 24th. They set a “buy” rating and a $11.00 target price on the stock. Cantor Fitzgerald started coverage on Entera Bio in a research report on Tuesday, September 22nd. They set an “overweight” rating for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Entera Bio in a research note on Friday, July 17th. Finally, Wall Street Zen raised Entera Bio to a “sell” rating in a report on Saturday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $9.60.

Get Our Latest Analysis on Entera Bio

Entera Bio Stock Up 9.3%

The company has a 50 day moving average of $2.93 and a two-hundred day moving average of $1.89. The firm has a market cap of $511.16 million, a P/E ratio of -8.27 and a beta of 1.38.

Entera Bio (NASDAQ:ENTX – Get Free Report) last issued its quarterly earnings results on Friday, August 7th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.06). Research analysts expect that Entera Bio Ltd. will post -0.4 earnings per share for the current fiscal year.

Institutional Trading of Entera Bio

A hedge fund recently bought a new stake in Entera Bio stock. Seven Fleet Capital Management LP bought a new position in shares of Entera Bio Ltd. (NASDAQ:ENTX – Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 135,318 shares of the company’s stock, valued at approximately $263,000. Seven Fleet Capital Management LP owned approximately 0.30% of Entera Bio as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 14.11% of the company’s stock.

About Entera Bio

(Get Free Report)

Entera Bio Ltd. is a biotechnology company developing orally administered therapies based on large-molecule drugs, including proteins and peptides that are traditionally delivered by injection. The company’s proprietary delivery technology is designed to help these molecules pass through the gastrointestinal tract and reach the bloodstream, with the goal of improving convenience and patient adherence.

Entera Bio’s lead programs have focused on bone and mineral disorders. Its pipeline has included EB613, an oral formulation of parathyroid hormone (PTH 1-34, or teriparatide) being developed for the treatment of osteoporosis, and EB612, an oral PTH product candidate intended for hypoparathyroidism.